TSH Biopharm was established from the parent company, TTY BioPharm Co., Ltd. TSH is committed to the development of patented cardiovascular and autoimmune products with economic benefits and high barriers. TSH Biopharm integrates product research and development, marketing, and training for the management of these disease categories in order to become an international drug development and marketing biotech pharmaceutical company.
In addition, TSH Biopharm has launched a dual-engine strategy to formally step into the field of precision medicine, providing comprehensive testing services for genetic testing of healthy Chinese people, liquid cell and genetic testing for cancer patients, and expanding the core expertise of chronic diseases to severe chronic diseases.
Contact
1503, 3/F, No. 1, 3, Park Street, Nangang District, Taipei, Taiwan
Tel: +886-02-2655-8525
Grace Yang, general manager of TSH Biopharm, discusses how the company is uniquely positioned to deliver end-to-end healthcare solutions to the APAC region in the areas of cardiovascular, gastrointestinal, autoimmune,…
Dr Chen-Yu Cheng, founder and chairman at Formosa Laboratories & Pharmaceuticals, is leading a strategic transition from generic API manufacturing toward high- value CDMO services and innovative drug development. By…
Siegfried Gschliesser, co-founder and CEO of Anya Biopharm, has spent over two decades shaping the pharmaceutical landscape in Asia. Under his guidance, Anya has pioneered a proprietary oral peptide delivery platform,…
Sabrina Zimmerman, General Manager for Taiwan, Hong Kong, and Macau and APAC (excluding Japan) Portfolio Head at Biogen, shares her perspective on the company’s expanding presence in Asia and its…
Dr Cyrus Yang, CEO of Taiwan Bio Therapeutics, outlines how he transformed the company – founded in 2014 with proprietary MSC‑expansion technology – into a global innovator in cell and gene therapy.…
Taiwan’s clinical research ecosystem has evolved rapidly in recent years, reflecting Asia’s growing role in global drug development. Samuel Su, Founder and CEO of Bestat Pharmaservices, discusses how the organisation…
Boston Scientific’s Dan Silver reflects on his global leadership journey and the evolution of the company’s presence in one of Asia’s most advanced healthcare systems. Silver discusses Boston Scientific’s growth…
Bringing together clinical scale, academic depth, and a strong engineering mindset, China Medical University Hospital has positioned itself as more than a care provider. In this interview, Dr Der-Yang Cho,…
Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for…
Promoted to General Manager of Moderna Taiwan in 2024, Wenchi Liu brings over 20 years of pharmaceutical industry experience spanning commercial strategy and operations. Since joining Moderna in 2023, she…
Professor Yun-Ching Fu serves as Superintendent of Taichung Veterans General Hospital, Taiwan’s largest national medical centre in the central region. A paediatric interventional cardiologist by training, Professor Fu established Taiwan…
Jack Chiu is leading Siemens Healthineers’ transformation from equipment supplier to value-based healthcare partner in Taiwan. Under the 2026–2030 “Elevating” strategy, Taiwan serves as an Asia-Pacific innovation landing pad, validating…
The TGPA’s Tiffany Chen brings over three decades of experience at the intersection of pharmaceuticals, public policy, and industry development. In her current role, she leads advocacy efforts to strengthen…
See our Cookie Privacy Policy Here
